BMRN logo

BMRN
Biomarin Pharmaceutical Inc. - Registered Shares

5,337
Mkt Cap
$10.55B
Volume
386,798.00
52W High
$66.28
52W Low
$50.76
PE Ratio
30.80
BMRN Fundamentals
Price
$54.90
Prev Close
$54.88
Open
$54.71
50D MA
$58.02
Beta
0.69
Avg. Volume
2.02M
EPS (Annual)
$1.80
P/B
1.73
Rev/Employee
$1.01M
$10,813.39
Loading...
Loading...
News
all
press releases
Choreo LLC Has $313,000 Holdings in BioMarin Pharmaceutical Inc. $BMRN
Choreo LLC lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 84.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·8h ago
News Placeholder
More News
News Placeholder
Sumitomo Mitsui Trust Group Inc. Cuts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN
Sumitomo Mitsui Trust Group Inc. reduced its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 97.4% in the 4th quarter, according to the company in its most recent 13F filing...
MarketBeat·1d ago
News Placeholder
Robeco Institutional Asset Management B.V. Sells 169,034 Shares of BioMarin Pharmaceutical Inc. $BMRN
Robeco Institutional Asset Management B.V. reduced its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 18.1% during the fourth quarter, according to the company in its most...
MarketBeat·7d ago
News Placeholder
Paragon Capital Management Inc. Invests $1.19 Million in BioMarin Pharmaceutical Inc. $BMRN
Paragon Capital Management Inc. purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 20,040 shares of the biotechno...
MarketBeat·8d ago
News Placeholder
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of "Moderate Buy" by Analysts
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-four analysts that are currently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold rating, sixteen have ass...
MarketBeat·12d ago
News Placeholder
Perpetual Ltd Grows Stake in BioMarin Pharmaceutical Inc. $BMRN
Perpetual Ltd increased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 425.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,621 shares of the biotechnol...
MarketBeat·16d ago
News Placeholder
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Increased to Strong-Buy at Truist Financial
Truist Financial raised BioMarin Pharmaceutical to a "strong-buy" rating in a research report on Wednesday...
MarketBeat·26d ago
News Placeholder
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·27d ago
News Placeholder
Swiss Life Asset Management Ltd Sells 54,282 Shares of BioMarin Pharmaceutical Inc. $BMRN
Swiss Life Asset Management Ltd decreased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 72.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,285 shares of the biotechnology company's stock after selling...
MarketBeat·28d ago
News Placeholder
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Down - Time to Sell?
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Down - What's Next...
MarketBeat·1mo ago
<
1
2
...
>

Latest BMRN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.